Results 121 to 130 of about 510,697 (405)

Secukinumab in the treatment of psoriasis: patient selection and perspectives. [PDF]

, 2018
Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Beck, Kristen M, Liao, Wilson, Yang, Eric J   +2 more
core   +1 more source

Psoriasis and Psoriatic Arthritis Cardiovascular Disease Endotypes Identified by Red Blood Cell Distribution Width and Mean Platelet Volume

Journal of Clinical Medicine, 2020
In a subset of psoriasis (PsO) and psoriatic arthritis (PsA) patients, the skin and/or joint lesions appear to generate biologically significant systemic inflammation. Red cell distribution width (RDW) and mean platelet volume (MPV) are readily available
R. Conic, G. Damiani, K. Schrom, A. Ramser, Chunlei Zheng, Rong Xu, T. McCormick, K. Cooper   +7 more
semanticscholar   +1 more source

Clinical Significance of Gut Microbiota Community Types for Long‐Term Response to Fecal Microbiota Transplantation in Patients With Psoriatic Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Fecal microbiota transplantation (FMT) holds promises as a beneficial supplement to methotrexate in patients with psoriatic arthritis (PsA). We therefore investigated how gut bacterial signatures in patients and donor strain engraftment were associated with long‐term response to FMT.
Panpan Qin, Maja S. Kragsnaes, Dorte K. Holm, Hans Christian Horn, Anna Christine Nilsson, Jens Kjeldsen, Karsten Kristiansen, Torkell Ellingsen   +7 more
wiley   +1 more source

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis. [PDF]

, 2018
To compare disease burden and biologic use among psoriatic arthritis (PsA) or rheumatoid arthritis (RA) patients recruited to the Corrona registry. Retrospective study of patients with PsA or RA enrolled in Corrona between January 2002 and March 2013 and
Etzel, Carol J, Greenberg, Jeffrey D, Griffith, Jenny, Karki, Chitra, Kavanaugh, Arthur, Kremer, Joel M, Singh, Rakesh   +6 more
core   +1 more source

Transition From Psoriasis to Psoriatic Arthritis is Characterized by Distinct Alterations in Peripheral Blood Tc17, Th17, and CD4+ Effector Memory Cells

Arthritis &Rheumatology, EarlyView.
Objective Cellular mechanisms driving transition from psoriasis to psoriatic arthritis have remained largely elusive. Thus, we investigated changes within the peripheral blood T cell compartment associated with the transition phase. Methods In an observational study, 116 patients were examined and categorized into subgroups including psoriasis with at ...
Hanna Graßhoff, Sara Comdühr, Henry Nording, Jacob von Esebeck, Philine Letz, Miriam Prohaczka, Handan Gedik, Henner Zirpel, Elisabeth Spallek, Linh Ha‐Wissel, El‐Baraa Adjailia, Sabrina Arnold, Konstantinos Fourlakis, Sebastian Klapa, Ingo Eitel, Oliver J. Müller, Jens Y. Humrich, Gabriela Riemekasten, Diamant Thaçi, Peter Lamprecht   +19 more
wiley   +1 more source

CLINICAL PRESENTATION OF PSORIATIC ARTHRITIS

Reumatismo, 2011
Psoriatic arthritis is a spondyloarthropathy, which occurs in patients with skin and/or nail psoriasis. Basing its characterization on morphological purposes, several types of arthritis have been described.
M. Atteno, R. Peluso, R. Scarpa
doaj   +1 more source

Seronegative spondyloarthropathies : a review : part II: genetics and pathogenesis [PDF]

, 1993
In none of the spondyloarthropathies is the pathogenesis well understood. Much of the investigation into the aetio-pathogenesis of these diseases has focused on the association with HLA-B27 and the known triggering potential of certain infectious agents.
Borg, Andrew A., Dawes, Peter T., Hothersall, T.E.   +2 more
core  

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies [PDF]

, 2022
Peter C. Taylor, Andrew G. Bushmakin, Joseph C. Cappelleri, Pamela Young, Rebecca Germino, Joseph F. Merola, Gil Yosipovitch   +6 more
openalex   +1 more source

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force

Annals of the Rheumatic Diseases, 2017
Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results
J. Smolen, Monika Schöls, J. Braun, M. Dougados, O. FitzGerald, D. Gladman, A. Kavanaugh, R. Landewé, P. Mease, J. Sieper, T. Stamm, M. D. de Wit, D. Aletaha, X. Baraliakos, N. Betteridge, F. E. Van den Bosch, L. Coates, P. Emery, L. Gensler, L. Gossec, P. Helliwell, Merryn Jongkees, T. Kvien, R. Inman, I. McInnes, M. Maccarone, P. Machado, A. Moltó, A. Ogdie, D. Poddubnyy, C. Ritchlin, M. Rudwaleit, A. Tanew, B. Thio, D. Veale, K. de Vlam, D. M. van der Heijde   +36 more
semanticscholar   +1 more source

Treatment persistence of biologics among patients with psoriatic arthritis

Arthritis Research & Therapy, 2020
Background Persistence of biologic therapy in psoriatic arthritis (PsA) patients is an important factor in individualized patient treatment planning and healthcare policy and guideline development. Objective To estimate the persistence of biologic agents
A. Haddad, T. Gazitt, I. Feldhamer, J. Feld, A. Cohen, I. Lavi, Faten Tatour, I. Bergman, D. Zisman   +8 more
semanticscholar   +1 more source